Association of antihypertensives during hospitalisation with acute respiratory failure in patients with viral pneumonia: A population‐based case‐control study. Issue 12 (25th September 2021)

• Record Type: Journal Article
• Authors: Lin, Shih‐Yi; Sung, Fung‐Chang; Lin, Cheng‐Li; Lin, Cheng‐Chieh; Hsu, Wu‐Huei; Liao, Wei‐Chih; Ho, Mao‐Wang; Lin, Po‐Chang; Hsu, Chung‐Y.; Kao, Chia‐Hung
• Is Part Of: International journal of clinical practice. Volume 75:Issue 12(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-25
• Subjects: acute respiratory failure (ARF) -- antihypertensive medications -- National Health Insurance Research Database -- viral pneumonia; Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.14776
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract: Background: We aimed to identify associations between the risk of acute respiratory failure (ARF) and types of antihypertensive agents in patients with viral pneumonia. Methods: In this case‐control study, data extracted from the Taiwan National Health Insurance Research Database were analysed. The base population comprised patients with viral pneumonia treated from 2000 to 2013. The case group comprised patients with ARF and the control group comprised participants without ARF. Adjusted odds ratios (ORs) were calculated using a multivariable logistic regression model. Results: In total, 4427 viral pneumonia patients with ARF and 4427 matched control participants without ARF were recruited. Patients with diabetes, alcohol‐related disease, asthma, chronic kidney disease or end‐stage renal disease, chronic obstructive pulmonary disease, cancer, congestive heart failure, stroke, acute pulmonary oedema and shock had increased odds of developing ARF, especially shock (adjusted OR = 49.3; 95% CI = 27.4, 88.7), cancer (12.6; 8.67, 18.2) and stroke (7.51; 5.32, 10.6). Increasing odds of developing ARF were noted in patients using potassium‐sparing diuretics (2.95; 1.54, 5.64), loop diuretics (68.2; 48.1, 96.6), calcium channel blockers (1.64; 1.26, 2.13) and angiotensin‐converting enzyme inhibitors (1.70; 1.15, 2.53). Patients with prescriptions of α‐blockers (0.44; 0.26, 0.74), β‐blockers (0.37; 0.26, 0.52), thiazides (0.38; 0.25, 0.59) and angiotensin receptor blockers (0.65; 0.51, 0.83) had lower odds of having ARF. Conclusion: Patients with viral pneumonia who received α‐blockers, β‐blockers, thiazides or angiotensin receptor blockers during hospitalisation had a lower risk of developing ARF.